Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:7/1/2008

in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals Conference Call Notice
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
6. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
7. Pharmasset Receives Notice of Allowance
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  In recognition of ... commitment to the global bleeding disorders community, CSL ... million international units (IUs) of protein therapies to the ... not-for- profit organization which has worked to improve the ... disorders. The donation supports the WFH,s Global Alliance for ...
(Date:2/27/2015)... 27, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... Officer, will present live at VirtualInvestorConferences.com on March ... join us for this Company update," said Mr. ... commercial launch of the exVive3D Liver, Bioprinted Human ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... data presented at the 60th Annual Meeting of the ... American Academy of Neurology (AAN) in Chicago, SMYRNA, ... pooled analyses of Phase II and III double-blind, randomized,placebo-controlled clinical ... data, which were presented at,the 60th Annual Meeting of the ...
... 16 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... independent data safety monitoring board (DSMB) has,recommended continuation ... to,determine whether a brief intravenous infusion of Viprinex(TM) ... functional outcome at 3,months. This is the fifth ...
Cached Medicine Technology:Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 2Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 3Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod) 2
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Kaylie Corrigan, ... alcohol treatment center , and current student obtaining her ... has implemented a weekly forum in psychoeducation on substance ... in Flagstaff, AZ as part of her studies. , ... need for support and counseling at the high school ...
(Date:2/28/2015)... 28, 2015 The noted Toronto plastic ... Surgery was recently featured in the January/February 2015 issue ... Dr. David Ellis was featured in an article entitled ... cosmetic enhancements that Kim Cattrall has possibly undergone to ... forehead is smooth without horizontal lines or frown line ...
(Date:2/28/2015)... Aliso Viejo, California (PRWEB) February 28, 2015 ... the release of TransFold Volume 2. A fully customizable ... Pro X. , “TransFold Volume 2 gives users total ... users,” said Christina Austin, CEO of Pixel Film Studios. ... Cut Pro X editor.” , TransFold Volume 2 from ...
(Date:2/28/2015)... Los Angeles, California (PRWEB) February 28, 2015 ... Tagarao fully supported and showcased emerging brand at ... Convention held in Las Vegas sending its executive ... and Director of Business Development and Training Randolph ... Franchise Association (IFA), was held last February 4-7 ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3
... an expanding waist line, weight gain and a tendency to ... a study published today in the journal Nature Genetics. ... significantly more common in those with Indian Asian than European ... Foundation, could lead to better ways of treating obesity. , ...
... hospitalizing young children for influenza creates a significant economic ... preventive flu shots for children and the people with ... by Cincinnati Childrens Hospital Medical Center and presented May ... Honolulu, Hawaii. , After analyzing data in three U.S. ...
... reflux, urinary incontinence ,slow down, seniors, studies say ... studies show that anticholinergics, a commonly prescribed group of ... their daily physical activities. , The two reports from ... findings released a few weeks ago that anticholinergic drugs ...
... no health insurance don,t see a doctor all year ... children share at least one frightening fact: If they are ... health care... period. , New research from the University ... children in families earning between $38,000 and $77,000 annually who ...
... and $77,000 a year are just as likely to ... poorer families. More than 40 percent of children in ... no physicians and have no prescriptions all year, according ... Center. , Theres an assumption that children in families ...
... Australian researchers have unveiled a new immunotherapy technique ... to AIDS. Details of the simple, cost-effective ... journal PLoS Pathogens. , There is an overwhelming ... therapies are expensive, impractical, and often highly toxic. ...
Cached Medicine News:Health News:Gene sequence that can make half of us fatter is discovered 2Health News:Young children hospitalized for flu associated with higher costs and higher risk illness 2Health News:Common Medications Could Cause Physical Impairment in the Elderly 2Health News:Middle Class Uninsured Kids' Health Risk Almost as High as Poor Children's 2Health News:Uninsured kids in middle class have same unmet needs as poor 2Health News:Uninsured kids in middle class have same unmet needs as poor 3
... The Gemini Family of infusion ... with a collective series of ... product line offers a wide ... IV sets, each featuring the ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... itself to over 2,000 medical clinics nation ... user in mind, ChartingPlus relies heavily on ... features to improve documentation quality and increase ... Our medical content is specific to your ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
Medicine Products: